Archive for September, 2014
CEO to Present Data Analysis of Colorectal Cancer Pilot Study of Approximately 1,000 Subjects
NAMUR, Belgium, Sept. 5, 2014 — VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types, today announced that its Chief Executive Officer, Cameron Reynolds, is scheduled to present at the Aegis Capital 2014 Healthcare & Technology Conference, being held September 10-13, 2014 at The Encore at Wynn Hotel in Las Vegas, NV.
Mr. Reynolds will present on Thursday, September 11, 2014 at 9:00 a.m. PT. During his presentation, he will discuss top-line results from analysis of an initial representative 938-subject sample from VolitionRx’s 4,800-subject retrospective colorectal cancer blood diagnostic pilot study at Hvidovre Hospital, Denmark. Mr. Reynolds will also outline VolitionRx’s business milestones and growth strategy.
VolitionRx’s NuQ® tests utilize the Company’s proprietary Nucleosomics® platform, which identifies and measures circulating nucleosome structures for the presence of epigenetic cancer signals within the blood. As part of the Denmark trial, VolitionRx is analyzing samples from approximately 4,800 subjects with colorectal cancer, polyps or adenomas, benign bowel diseases or other malignancies, all of whom have undergone a colonoscopy. Under the trial design, VolitionRx has full access to all Danish national registries and databases. The trial is designed to evaluate the diagnostic accuracy of the NuQ® test for colorectal cancer.
Details of the presentation are as follows:
| Date: |
Thursday, September 11, 2014 |
| Time: |
9:00 a.m. PT |
| Location: |
The Encore at Wynn Hotel in Las Vegas, Nevada |
Investors attending the Conference who would like to schedule a 1-on-1 meeting with VolitionRx management during the conference may do so by contacting their Aegis Capital Corp. representative, or Lee Roth of The Ruth Group at lroth@theruthgroup.com.
For those unable to attend, a live webcast of Mr. Reynolds’ presentation will be available on the Company’s website at www.volitionrx.com. Following his presentation, this webcast will be archived for 90 days.
About VolitionRx
VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.
VolitionRx’s goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx’s research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.
Visit VolitionRx’s website (www.volitionrx.com) or connect with us on Twitter, LinkedIn, Facebook or YouTube.
Safe Harbor Statement
Statements in this press release may be “forward-looking statements”. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission.
Media Contacts
Charlotte Reynolds, VolitionRx
Telephone: +44 (0) 795 217 7498
Email: Charlotte.Reynolds@volitionrx.com
Kirsten Thomas, The Ruth Group
kthomas@theruthgroup.com
Telephone: +1 (646) 536-7014
Investor Contacts
Scott Powell, Investor Relations
S.Powell@volitionrx.com
Telephone: +1 (917) 721-9480
Lee Roth, The Ruth Group
lroth@theruthgroup.com
Telephone: +1 (646) 536-7012
Audited Financials and Strict Management to Build the Base for the New Contracts
LONDON, UNITED KINGDOM–(Sep 4, 2014) – E-Waste Systems, Inc. (OTCQB: EWSI) (‘EWSI,’ ‘the Company,’ or “eWaste Systems”) an electronic waste management, environmentally focused services and technology company, announces the formation of a new subsidiary EWS-China Ltd to lead the operations in East Asia.
In China sales of electronic devices are surging, generating as much as 2.3 million tonnes of electronic waste domestically each year, according to a 2010 report by the United Nations Environmental Program (UNEP). According to the report, e-waste production in China and South Asia is predicted to grow 200-400% by 2020, second only to the United States, which produces three million tonnes annually. The national market is not the only source for discarded electrical and electronic equipment (“EEE”) in China where, despite the country’s ban on all e-waste imports, enacted in 2000, legal loopholes on trans-boundary imports are largely tolerated.
Despite improvements to treatment facilities in recent years, China still lacks sufficient high-tech recycling facilities and relies instead on environmentally damaging methods of disposal. Some e-waste is burned and large amounts of hazardous material are abandoned without treatment, according to a report by China Environment News.1
“The considerable effort and resources deployed to penetrate the tremendous and fast-growing Chinese market is beginning to reap some of the vast potential. We have learned a great deal and now have a formula to overcome previous obstacles key among which is the process to defer risk until results can be properly measured and audited. With the bulk of the investment behind us, we are now positioned to take advantage of the significant network we have created,” said Mr. Martin Nielson, Founder & CEO of E-Waste Systems.
The new plan implemented to proceed with the expansion strategy in East Asia is managed through a new subsidiary, EWS-China Ltd. An Executive Committee formed with both internal and external experienced resources will guide the operations. The company will be independently capitalized in order to design and develop ventures and support operations related to the eWaste, eVolve and eIncubator business units.
Partnership with an leading accounting firm with an understanding of the China market and business practices while focused on US GAAP will provide, from day one, the consistent support to review all the contracts — either already existing or those that will be entered into in the future — to achieve the consolidation of balance’s final result. Regular reporting, US GAAP accounting, proper financial controls, and full managerial responsibility provide the best practice tools to manage the operations, maintaining the full commitment to the highest standards and complete sustainability.
“We are receiving requests nearly daily for solutions to the massive problem developing and rapidly expanding in countries where more than two decades of indiscriminate landfilling has caused an enormous plague. The magnitude of the issue is the impetus behind out drive to provide a concrete and reliable solution for proper disposal of electronics,” said Mr. Nielson. “Our experience in China has provided a model we can replicate and apply in other high risk markets proving that a strategy based on the sustainability can produce benefits for the environment and the community together with profitability,” added Mr. Nielson.
According to a new market research report the revenue generated from the e-waste management market is expected to grow from $9.15 billion in 2011 to $20.25 billion in 2016 at a rate of 17.22 percent. Management of e-waste provides benefits such as job creation, improved technological knowledge, and environmental benefits. In developing countries, job creation also helps in alleviation of poverty and improved health conditions.2
For information, video and pictures follow E-Waste Systems, Inc. on LinkedIn & Facebook, @EWasteSystemsIn on Twitter and on the Company’s website www.ewastesystems.com.
For additional inquiries, contact Investor Relations at: ir@ewastesystems.com.
About E-Waste Systems, Inc.
E-Waste Systems, Inc. is the first pure play public company in the emerging waste electrical and electronics equipment (“WEEE”) industry. EWSI leverages its expansive geographical network of affiliates providing best practices in professional management and state-of-the-art engineering to companies facing regulatory or other mandates for handling e-waste. Additional information, including the business plan summary, pictures and descriptions of the facilities, staff, and overall progress of the Company is available on the official website and social media sites: www.ewastesystems.com, Facebook, Twitter, and LinkedIn. Or contact: Investor Relations at: ir@ewastesystems.com.
Safe Harbor Statement: Certain statements and information included in this release may constitute “forward-looking statements” as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management’s projections, estimates and expectations is contained in the Company’s SEC filings. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.
1 http://www.ipsnews.net/2011/07/e-waste-hits-china/
2 http://www.marketsandmarkets.com/Market-Reports/electronic-waste-management-market-373.html
WILTON, CT / September 4, 2014 / Gold Coast Mining Corp. (OTC Pink: GDSM), provides update on its Colorado activities.
Gold Coast, a leader in innovative concepts and technologies in the marijuana industry, is excited to announce that the Company has reached a verbal agreement for a new grow opportunity and two other projects located in Routt County, CO.
A written term sheet has been submitted to parties for the acquisition/lease of a 3,600 sq. ft. warehouse that will accommodate a substantial grow operation with the capability to install a loft or second level, further expanding production capabilities. The warehouse has all the required infrastructure including 3 phase power and water and a harvest is planned for January/February timeframe and be perpetual thereafter. The Company is waiting on the final signature and will immediately move to final documentation.
Gold Coast and its Denver based legal counsel are performing due diligence on two other properties, one is a family owned 90 acre parcel of which only 40 acres are currently being used as an outdoor grow facility. Plans call to fully develop the 90 acres and construct several greenhouses to allow for year round cultivation.
The third property is a retail medical marijuana dispensary that has several valuable permits including MIP (Marijuana Infused Products) kitchen and wholesale grow licenses.
CEO Michael Shea commented, “I am pleased with the opportunities and I have no doubt that the Company will close transactions in the very, very short term. These transactions are complex and time consuming, but we have the legal structure that allows Gold Coast to participate. Routt County has been more consistent in its view of the industry versus Chaffee County, which just imposed a moratorium on new grow facilities, causing us to put that project on hold despite getting all parties to agree to the terms and conditions.”
“I fully expect events to start unfolding rapidly beginning next week and will keep shareholders and the investment community updated”, Shea concluded.
The o/s remains unchanged from previously reported.
ABOUT GOLD COAST MINING
Gold Coast Mining Corp. is a holding company with interests in the MJ industry. The Company’s goal is create a vertically integrated company and continue its diversification into other high growth industries. The primary goal is generate cash flow to sustain and grow profitability.
Follow us on Twitter at http://twitter.com/GoldCoastMining
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.
Contact Info:
Michael Shea
CEO
Gold Coast Mining Corp.
(203) 210-5614
Michael.shea@gdsmholdings.com
http://www.gdsmholdings.com
http://www.mj-xchange.com
http://www.mj-merchant.com
http://420concept.com
VANCOUVER, BRITISH COLUMBIA–(Sep 4, 2014) – Mobio Technologies Inc. (TSX VENTURE:MBO)(OTCQX:MBIOF), parent company of MobioINsider, the premier social network for social influencers and brands, is pleased to announce that it has entered into a revenue share agreement with GP Inc., producers of the “Where’s My Lamborghini” cross-platform, mobile map game, for Microsoft Mobile, Nokia Lumia, and Automobili Lamborghini.
The company will be working with GP Inc.’s Helsinki based executive team, Microsoft’s Lumia group, local media partners DMI, and Virgin Radio Dubai’s Kris Fade, for the upcoming game launch in Dubai, currently scheduled for Q4 2014. Microsoft are utilising GP Inc.’s cross-platform game concept for the roll-out of new Lumia handsets in the UAE, and other strategic global markets.
GP Inc. will integrate Mobio’s SMO (Social Media Optimization) streams; the INsider social network as the designated engagement platform, and the Strutta social promotions platform. The agreement provides for an equal revenue sharing program between GP Inc. and Mobio.
Mr. Pekka Sarssi, CEO of GP Inc. describes the concept; “The WML platform integrates the mobile map game – to find the Lamborghini somewhere in the UAE – and a reality-show style competition, packaged as an 8-part prime time TV series, featuring 6 finalist teams battling it out in a variety of mental and physical challenges, to win the new Lamborghini Huracán LP 610-4.”
The WML game application uses here.com maps for Smartphones running WP, iOS and Android operating systems. The WML platform is designed to create global, social media focused interactions, game-play entertainment, and will be delivering 40,000 instant rewards to participants. During the TV show, local celebrities are paired with each finalist and the teams compete against each other in activities ranging from paintball shoot-outs to skydiving. The teams will capture footage using their Nokia Lumia Smartphones as they video document their entire experience.
“Partnering with Mobio is an excellent opportunity that will bring great value to the promotion of the game, the TV program, and our global brand partners. Our brand fusion model is enhanced by Mobio’s SMO tools…robust and flexible, we can seamlessly integrate them into our communications and promotional strategy, including a customised INsider social platform… We are excited to be working with Mike and his talented team…”, said Mr. Sarssi.
“The WML cross-platform execution is an exciting implementation of social mobile engagement in an exciting geographical market,” said Mike Edwards, CEO of Mobio Technologies. “By including the Mobio INsider and Strutta streams, GP Inc. and Mobio Technologies are able to further increase engagement of fans during the competition, and capitalize upon the resulting revenue opportunities.”
About GP Inc.
GP Game Production Inc. is the owner and developer of the cross-platform mobile game and TV format, “Where’s My Lamborghini”. GP Inc. is a communications company that specialises in brand fusion activations utilising gameification and mobile technologies, to create high quality, cross-platform entertainment content. Their global brand partners include Microsoft Mobile, Nokia Lumia, and Automobili Lamborghini.
Their Brand Fusion concept is a through the line ATL/BTL and 360 degree cross-platform activation strategy, designed to entertain, engage and expand consumer touch points. GP create simple but exciting game concepts, that challenge and ignite users imaginations, and deliver relevant rewards throughout the activation.
About Mobio Technologies Inc.
Mobio Technologies is the parent company of MobioINsider, the premier social network for social influencers, with its “Be Social. Get Paid” revenue sharing platform. MobioINsider allows these influencers to monetize high rates of fan engagement. In addition to MobioINsider, Mobio operates Strutta, a social promotions platform that helps marketers bring potential customers from stranger to fan to customer. Mobio Technologies is a publicly traded company on the TSX-V and the OTCQX, headquartered in Vancouver, BC. To learn more, visit www.mobio.net.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS. Other than statements of historical fact, all statements included in this news release, including, without limitation, statements regarding future plans and objectives of Mobio Technologies are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Factors that could cause actual results to differ materially from those expected by Mobio Technologies are those risks described herein and from time to time, in the filings made by Mobio Technologies with Canadian securities regulators. Those filings can be found on the Internet at: http://www.sedar.com.
Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Liolios Group, Inc.
Scott Liolios
Investor Relations
1-949-574-3860
lxv@liolios.com
Salt Lake City, UT / September 4, 2014 / Infrastructure Developments Corporation (OTC: IDVC) announced today that Cyril Means III has accepted a position as a director and as secretary of the company.
“Cyril Means has extensive experience in United States securities law, mergers and acquisitions, and finance,” said IDVC CEO Eric Montandon. “We are actively pursuing acquisitions and his expertise will be critical in our due diligence process and our evaluation and pursuit of new business ventures.”
Mr. Means graduated from New York Law School in 1992 with a Juris Doctorate, and is currently licensed by the New York Bar Association. He served as in house counsel to J.J. Bonamuso & Company, a New York commercial real estate company, from 1993 to 1994, and served as General Counsel, Corporate Counsel, Vice President, and Executive Vice President with the Aegis Consumer Funding Group from 1995 to 1999, overseeing corporate and consumer compliance, negotiating credit facilities in excess of $1 billion, and serving as issuers’ counsel for the company’s asset backed securities program. He served as Vice President and General Counsel to Dollar Financial Group, Inc., from 1999 to 2005, completing numerous domestic and international mergers and acquisitions, negotiating credit facilities, and coordinating federal and state lobbying efforts on matters affecting the company. Mr. Means has been semi-retired since 2005.
Infrastructure Developments Corporation:
IDVC is a publicly listed project management firm headquartered in the United States. IDVC’s mission is to bring world-class execution to the international construction and project management industry, and to expand into selected complementary businesses in high-growth international markets. The company is currently focusing on expanding its recently acquired real estate brokerage firm in Dubai, U.A.E., and is also marketing prefabricated housing in North America, the Middle East, and parts of South-East Asia.
Forward-Looking Statements:
A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties including the company’s development, competitive market conditions, and its prospects for securing additional sources of financing as required. The actual results that the company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties. The company encourages the public to read the information provided here in conjunction with its most recent filings on Form 10-Q and Form 10-K. The company’s public filings may be viewed at www.sec.gov.
Contact:
Eric Montandon – CEO
Infrastructure Developments Corp., Inc.
eric@idvc.us
www.idvc.us
+971 50 553 2590
MIAMI, FL, United States, via ETELIGIS INC., 09/04/2014 – – Today Metrospaces, Inc. (OTC PINK: MSPC), (PINKSHEETS: MSPC), a real estate investment and development company focused on building & reselling condominiums and Luxury High-End Hotels, principally in urban areas of Latin America, is happy to announce that it has acquired the Coche Island hotel project located in Coche Island, Venezuela.
Metrospaces has recently acquired a 50% stake in this exceptional 28-villa luxury hotel and spa. The company has an option to acquire an additional 10% from current shareholders. This destination hotel will have 28 luxury villas of 680ft2 of space, each unit will have its own Jacuzzi and kitchen made for gourmet dinners specially ordered by our guests. This project will be aimed at the luxury destination segment with forecasted room rates of $300 per night.
This represents an amazing testament to our ability to drive value by finding amazing hotel development opportunities and being able to capitalize on them. We have hit the ground running on this project and are looking to have permits renewed and bank financing approved by 1Q of 2015, Mr. Brito said. This will be our second hotel project in Venezuela in only 9 months. We certainly expect to be able to continue to find exceptional hotel investment and development deals in the region.
VISUAL PRESENTATION DOWNLOAD LINK ON TULASIR VILLA SPA AND HOTEL:
https://db.tt/YYK50THw
VISUAL PRESENTATION ON ORINOCO HOTEL PROJECT LINK:
https://db.tt/pE9Bsfnr
For more information about Coche Island, please see:
http://en.wikipedia.org/wiki/Coche_Island
About Metrospaces:
Metrospaces www.metrospaces.net is a publicly traded real estate investment and development company which acquires land, designs, builds, develops, and then resells condominiums and Luxury High-End Hotels, principally in urban areas of Latin America. The companys current projects are located in Buenos Aires, Argentina, and Caracas, Venezuela.
Six years ago, Metrospaces shareholders saw a unique opportunity to participate in several exciting property markets around the world. Through their world-wide network of highly recognized real estate entrepreneurs, the company was able to capitalize on unique real estate development opportunities. Since Inception, the company has leveraged those relationships along with extensive financial expertise and transformed excellence by results.
Metrospaces is a boutique real estate development company, a product of the alliance of Metrospace shareholders, along with an elite group of real estate professionals and entrepreneurs located around the world. Company shareholders have extensive careers in real estate financing worldwide, and have funded projects both in the Americas and across Europe, valued in excess of US $350Million.
Metrospaces majority shareholders have partnered with Investors on Elite properties, including The London BVLGARI 5 Star Hotel, and is currently involved in negotiations for the development of several elite luxury properties in South America.
Among Metrospaces partners are architects, real estate developers, agents, and attorneys of the highest standing, with extensive experience in the global property market.
Metrospaces was originally founded by company president Oscar Brito.
Relevant Links:
www.metrospaces.net
Safe Harbor Statement:
Statements in this news release may be forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Metrospaces Inc. undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.
CONTACT:
Metrospaces, Inc.
Tel: 305-600-0407
Investor Relations:
investors@metrospaces.net
SOUTHLAKE, TX, United States, via ETELIGIS INC., 09/04/2014 – – Swordfish Financial, Inc. (OTC PINK: SWRF) (“SFI,” “Swordfish,” or the “Company”), a diversified investment and small business growth company today announced that its Board of Directors has appointed Susan Sjo as Chief Executive Officer and member of the Board of Directors effective immediately.
During this time of transformation, there is no better person to lead Swordfish Financial, Inc. than Susan Sjo, said Mr. Clark Ortiz, Chairman of the Board of Directors. Susan is a proven leader with hard-core financial skills, business vision and the ability to bring people together. Her vision and experience in the financial sector is exactly what Swordfish Financial, Inc. needs as the company enters its next chapter of growth.
Susan Sjo is the former CEO and CIO of St. Esprit R&T LLC, a multi-assest management consultancy. Susan is also the former Managing Director for Stack Capital, LLC and Sjo, Inc., a global macro CTA and Hedge Fund.
Susan Sjo has a B.A. with Honors in International Studies and Minor in Economics from the Barat College of DePaul University. In 1988, she was named Trader of the Year, by Futures Magazine, and in 1992 received the Trader of the Year honor by Business Week. In 1993, she received the Young Leaders Award Crains 40 Under 40 by Crains Chicago Business. Her previous Board of Director positions include Sjo, Inc., Manage Fund Association, New York Board of Trade, The New York Cotton Exchange, FINEX Exchange, Barat College, Sutain, and Visanow.com
About Swordfish Financial, Inc.
Swordfish Financial, Inc. (SFI) is a publicly held diversified financial company designed to acquire undercapitalized assets with a high level of profitability in the digital, entertainment, energy, commodities and Smart technology industries. SFI develops capital while providing valuable opportunity of loans and or investment in, small and medium sized organizations with the goal of increasing investor value.
Forward-Looking Statements:
Contained; forward-looking statements about management’s view of SFI’s future expectations, plans and prospects. Statements made are forward-looking which involve known and unknown risks, uncertainties and other factors, which may cause the results of SFI to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in documents that SFI files with the Securities and Exchange Commission, including but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks. SFI cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these statements. Finally, SFI undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by SFI.
Contact:
Contact Information: Investor Relations
Phone: 1-817-845-6244
Email: ir@SwordfishFinancial.com
www.Facebook.com/SwordfishFinancialInc
Twitter @SwordfishWorld
Podcast www.SwordfishNews.com
CYBK to Spin off Cyber-Thingy as a dividend to its shareholders
DEBARY, Fla., Sept. 3, 2014 — Cyber Kiosk Solutions, Inc. (OTC PINK: CYBK) is pleased to announce the Company has acquired EPA Petroleum, Inc.(EPA) as a wholly owned subsidiary for 300 million shares of Restricted Common stock and Nathan Hall has been appointed the sole officer and director of CYBK.
EPA Petroleum, Inc. will be the new operating company within CYBK. The former officers and directors have resigned and Christopher J Clarke is returning 65 million shares of Common stock back to the Company.
EPA Petroleum, Inc. (EPA) is an oil drilling company with operations in Pennsylvania. EPA currently has 4 groups of 10 Oil Well blocks to be able to drill on over 250 acres of land and has oil drilling underway on the same drilling lease. EPA focuses in on a niche area of drilling that is very conservative focusing in on benefits from the tax deductions available for an oil and gas drilling investment including intangible drilling costs, depreciation, operating costs, and percentage depletion. Structured properly, partners may offset their taxable income gained from other sources with the substantial deductions available from investing in oil and gas wells.
EPA currently targets oil drilling opportunities between 1 to 3000 feet in depth with most oil wells being between 1000 to 1300ft feet. This limits the risk of drilling a dry hole along with many other mitigating factors. EPA chooses its locations based on proven reserves and geology/nuclear well reports in the region. The company does NOT do any “Wild Cat Drilling” and EPA’s areas of drilling are in the vicinity of where Quaker State Oil, Pennzoil, and the Rockefeller families all began in the oil business.
After reviewing geology reports EPA’s oil drilling program expects between 850 to 1500 barrels of oil per well, in year one. Some wells in the area have produced higher yields in year one and oil yields may fluctuate. The company’s current operations are in the Oil City, Pennsylvania and Venango County, Pennsylvania areas that have historical proven reserves and are located within miles of the birth of the Oil Industry (Titusville, Pennsylvania). Due to hydraulic fracking, these areas have come back alive and are producing oil again.
At the end of June EPA had $300,000 in cash in the bank and has its own investment source, which has committed funds for future land leases and drilling operations. This gives the Company an advantage of not having to sell shares in the market to raise capital for future operations. The Company headed by Nathan Hall has agreed not to do a reverse split for a minimum of one year, allowing it time to evaluate market conditions.
The Company, simultaneously with the Closing of the EPA transaction, moved all of its contracts, agreements, LOI’s and any other agreement whether written or oral into Cyber-Thingy, Inc., of which Oren Manelis has been appointed as the Sole officer and director of the company.
The Company will file with FINRA to change the name, the symbol and effect a spin off of Cyber-Thingy, Inc., to its shareholders no later then October 10, 2014. Next week CYBK will announce an official record date and details for the Spin Off of Cyber-Thingy.
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
THOUSAND OAKS, Calif. and NORWALK, Conn., Sept. 3, 2014 — Teledyne Technologies Incorporated (NYSE:TDY) (“Teledyne”) and Bolt Technology Corporation (Nasdaq:BOLT) (“Bolt”) jointly announced today that they have entered into a definitive agreement that provides for the merger of Bolt with a wholly-owned subsidiary of Teledyne. Pursuant to the transaction, Teledyne will acquire all of the outstanding common shares of Bolt for $22.00 per share payable in cash. The definitive agreement contemplates that Bolt will pay its previously announced quarterly dividend of $0.09 per common share, payable on October 2, 2014, to stockholders of record on September 3, 2014. The aggregate value for the transaction is approximately $171 million, taking into account Bolt’s stock options and net cash as of March 31, 2014. The transaction was unanimously approved by the Boards of Directors of Teledyne and Bolt. In addition, Bolt’s directors and executive officers have agreed to vote their shares in favor of the transaction.
Since 1965, Bolt has been a leading supplier of marine seismic energy sources and replacement parts for offshore energy exploration. Bolt also develops and manufactures high-reliability underwater cables and connectors, as well as related electronic controllers, monitoring systems and other auxiliary equipment. Through its SeaBotix business, Bolt is a leading designer and manufacturer of miniature underwater remotely operated vehicles (Mini ROVs) used in maritime security, search and rescue, aquaculture, and scientific research applications.
“Bolt will broaden our rich portfolio of marine instrumentation with a number of highly complementary products,” said Dr. Robert Mehrabian, Chairman, President and Chief Executive Officer of Teledyne. “Bolt’s geophysical acoustic sources will fit well with our existing hydrophone arrays, which listen for the echoes from these sound sources. Bolt would also bring unique connector technology, products and customers to our subsea interconnect businesses. Finally, SeaBotix expands our marine systems business by adding inspection-class ROVs to our autonomous underwater vehicles (AUVs), while also providing more platforms to use our extensive line of marine sensors.”
Raymond M. Soto, Bolt’s Chairman and Chief Executive Officer, commented, “This transaction rewards our shareholders, while providing exciting opportunities for both our customers and employees. Our respective companies have complementary products and technology, and given Teledyne’s resources, we believe that we can accelerate the development of new products, such as our environmentally friendly marine seismic energy source.”
Johnson Rice & Company L.L.C. is acting as exclusive financial advisor and Levett Rockwood P.C. and Edwards Wildman Palmer LLP are acting as legal counsel to Bolt. McGuireWoods LLP is acting as legal counsel to Teledyne.
About Teledyne Technologies
Teledyne Technologies is a leading provider of sophisticated instrumentation, digital imaging products and software, aerospace and defense electronics, and engineered systems. Teledyne Technologies’ operations are primarily located in the United States, Canada, the United Kingdom, and Western and Northern Europe. For more information, visit Teledyne Technologies’ website at www.teledyne.com.
About Bolt Technology Corporation
Bolt Technology Corporation is a leading worldwide developer and manufacturer of marine seismic data acquisition equipment used for offshore oil and natural gas exploration. Bolt, through its SeaBotix Inc. subsidiary, is also a developer and manufacturer of remotely operated robotic vehicles systems used for a variety of underwater tasks.
Additional Information About the Acquisition and Where to Find It
This press release is for informational purposes only. It does not constitute an offer to purchase shares of Bolt Technology Corporation or a solicitation or recommendation statement under the rules and regulations of the SEC. Bolt will publicly file a Form 8-K with the SEC containing the terms of the definitive merger agreement, and plans to mail a proxy statement to stockholders of Bolt in connection with the proposed transaction. Investors and security holders of Bolt are urged to read the proxy statement and other relevant materials when they become available because they will contain important information about Teledyne, Bolt and the proposed transaction. Investors and security holders may obtain a free copy of these materials (when they are available) and other documents filed with the Securities and Exchange Commission at the SEC’s web site at www.sec.gov. A free copy of the proxy statement, when it becomes available, may also be obtained from Bolt Technology Corporation, Four Duke Place, Norwalk, Connecticut 06854, Attn: Investor Relations. In addition, investors and security holders may access copies of the documents filed with the SEC by Bolt on Bolt’s web site at www.bolt-technology.com. Bolt, Teledyne and their executive officers and directors may be deemed to be participants in the solicitation of proxies from its stockholders with respect to the proposed transaction. Information regarding the interests of the officers and directors of Bolt in the proposed transaction will be included in the proxy statement, and information regarding the officers and directors of Teledyne is included in its most recent Annual Report on Form 10-K and its most recent Proxy Statement filed with the SEC. The consummation of the proposed transaction is subject to the approval of Bolt’s stockholders as well as other customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
Forward-Looking Information Cautionary Notice
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, with respect to management’s beliefs about the financial condition, results of operations and businesses of Teledyne and Bolt in the future. Forward-looking information involves risks and uncertainties, is based on the current expectations of the management of Bolt and Teledyne and is subject to uncertainty and changes in circumstances. The forward-looking information contained herein may include statements about the expected effects on Teledyne of the transaction, the anticipated timing and scope of the transaction, expected timing of the completion of the transaction, anticipated earnings enhancements, estimated cost savings and other synergies, costs to be incurred in achieving synergies, anticipated capital expenditures and product developments, other strategic options and all other statements in this announcement other than historical facts. Forward-looking information includes, without limitation, statements typically containing words such as “intends”, “expects”, “anticipates”, “targets”, “estimates” and words of similar import. By its nature, forward-looking information is not a guarantee of future performance or results and involves risks and uncertainties because it relates to events and depends on circumstances that will occur in the future. Actual results could differ materially from this forward-looking information. Many factors could change anticipated results, including Teledyne’s ability to integrate Bolt’s operations, retain customers and key employees and achieve operating synergies, the ability to develop and market new competitive products, risks associated with global economic conditions and fluctuations in offshore energy activity, failure of the requisite number of Bolts stockholders to approve the transaction, operating results of Bolt being lower than anticipated, and unexpected acquisition-related costs and expenses. Certain of these and other factors that could affect Bolt’s business are discussed in Bolt’s Annual Report for the fiscal year ended June 30, 2013 and Bolt’s Quarterly Reports on Form 10-Q for the periods ending September 30, 2013, December 31, 2013 and March 31, 2014. Additional information concerning factors that could cause actual results to differ materially from those projected in the forward-looking statements is contained in Teledyne’s periodic filings with the Securities and Exchange Commission, including its 2013 Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Neither Teledyne nor Bolt undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
CONTACT: Jason VanWees
SVP, Strategy and M&A
Teledyne Technologies
(805) 373-4542
Raymond M. Soto
Chairman and CEO
Bolt Technology Corporation
(203) 853-0700
Conference Call Today at 11:00 AM ET
BUFFALO, NY–(Sep 3, 2014) – Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the minutes from its meeting with the U.S. Food and Drug Administration (FDA) in July confirmed that the Company’s existing efficacy and safety data and animal-to-human dose conversion are sufficient to proceed with a pre-Emergency Use Authorization (pre-EUA) submission for entolimod for reducing the risk of death following exposure to potentially lethal irradiation occurring as the result of a radiation disaster.
Yakov Kogan, Ph.D, MBA, Chief Executive Officer of Cleveland BioLabs, stated, “The outcome of our FDA meeting is very positive and we are pleased with the agreements we have reached with the agency. Our achievement of animal-to-human dose conversion and the FDA’s acknowledgement of the conceptual soundness of our dose-conversion methods are significant milestones in entolimod’s development under the FDA’s Animal Rule.”
“We are starting preparations for a pre-EUA application which, if authorized, would allow for entolimod’s use in the event of a radiological or nuclear emergency. In parallel, we are continuing our discussions with various U.S. government agencies regarding potential co-sponsorship and support for a pre-EUA submission for entolimod, as well as ongoing funding for the remaining development steps required for full licensure. We believe that entolimod has enormous potential to save lives as part of the nation’s defense against a radiological or nuclear disaster and are dedicated to moving its development forward.”
A pivotal efficacy study conducted in 179 non-human primates (NHPs) demonstrated that a single intramuscular injection of entolimod given 25 hours after high-dose, whole-body irradiation increased survival from 27.5% in control animals to 75% in treated animals — a highly statistically significant, nearly three-fold improvement. These results were obtained without the use of any antibiotics or supportive care. A second, pivotal dose-conversion study conducted in 160 NHPs established the dose-dependent effect of entolimod on biomarkers for efficacy in non-irradiated NHPs.
Clinical studies of entolimod in 150 healthy human subjects have demonstrated the safety profile of entolimod and established the dose-dependent effect of entolimod on efficacy biomarkers in humans. In addition, entolimod has been administered to 25 patients with advanced cancer in an ongoing Phase 1 study.
The FDA has granted Fast Track status to entolimod and Orphan Drug status for prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster.
Conference Call Information
Cleveland BioLabs management will host a conference call at 11:00 a.m. ET today to discuss these developments and address questions. Interested parties may participate by dialing 877-407-9205 (US) or 201-689-8054 (International), approximately five to ten minutes before the call start time. A live webcast of the conference call will be available on the Investors page of the Cleveland BioLabs web site at www.cbiolabs.com. A replay of the call will be available starting on September 3, 2014, at 2:00 p.m. ET through September 17, 2014, at 11:59 p.m. ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering conference ID number 13589652. An archived webcast of the conference call will be available for 90 days on the Investors page of the Cleveland BioLabs web site at www.cbiolabs.com.
About Cleveland BioLabs
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company’s lead product candidates are entolimod, which is being developed for a biodefense indication and as a potential cancer treatment and Curaxin CBL0137, our lead oncology product candidate. The company conducts business in the United States and in the Russian Federation through our three operating subsidiaries, Incuron, LLC, BioLabs 612, LLC and Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children’s Cancer Institute Australia. To learn more about Cleveland BioLabs, Inc., please visit the Company’s website at http://www.cbiolabs.com.
This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as “expect(s),” “feel(s),” “believe(s),” “will,” “may,” “intend,” “would allow,” “potential” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the safety of entolimod, the ability of entolimod to increase survival rates after irradiation, our ability to successfully develop and commercialize entolimod; the conduct and results of our various clinical trials; our ability to obtain pre-EUA approval from the U.S. Food and Drug Administration for entolimod and subsequent full licensure; our ability to find partnerships and sources of funding to a pre-EUA submission and full licensure; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.
These risks and uncertainties include, among others, the Company’s inability to demonstrate the safety and efficacy of entolimod as a radiation countermeasure, the Company’s failure to successfully and timely develop entolimod and existing and new products; the Company’s inability to obtain EUA approval for entolimod and subsequent full licensure; the Company’s collaborative relationships, including the Company’s inability to obtain co-sponsorship and financial support for the development of entolimod from U.S. government agencies, and the financial risks related thereto; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company’s ability to comply with its obligations under license agreements; the Company’s history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the “Risk Factors” and “Forward-Looking Statements” described in the Company’s periodic filings with the Securities and Exchange Commission.
Contact:
Rachel Levine
Vice President Investor Relations
Cleveland BioLabs, Inc.
T: (917) 375-2935
E: rlevine@cbiolabs.com
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it has entered into a master clinical supply agreement with Roche under which Roche will supply GazyvaTM (obinutuzumab) to Infinity for use in planned clinical studies to evaluate the combination of Gazyva and duvelisib (IPI-145), Infinity’s oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with hematologic malignancies, or blood cancers. The companies have also entered into a material transfer agreement under which Infinity is supplying Roche with duvelisib for use in Roche’s preclinical and translational research to evaluate the combination of duvelisib and Gazyva.
“We believe that duvelisib has the potential to be the best-in-class PI3K inhibitor and that Gazyva has the potential to be the best-in-class anti-CD20 therapy, so we are pleased to have entered into these agreements with Roche. Our ability to evaluate duvelisib in combination with Gazyva in multiple clinical studies is part of Infinity’s strategy to combine duvelisib with both current standards of care and novel, targeted therapies,” stated Julian Adams, president of research and development at Infinity. “We look forward to beginning clinical studies of duvelisib plus Gazyva, including the first study in indolent non-Hodgkin lymphoma evaluating Gazyva in combination with a PI3K inhibitor.”
In 2014, Infinity plans to initiate a Phase 1b/2 clinical study of duvelisib in combination with Gazyva or rituximab in patients with previously untreated indolent non-Hodgkin lymphoma (iNHL). Infinity also expects to initiate in 2014 a Phase 1b clinical study of duvelisib in combination with Gazyva in patients with chronic lymphocytic leukemia (CLL) whose disease has progressed following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. These studies are in addition to Infinity’s plans to initiate this year DYNAMO+RTM, a global Phase 3 study evaluating duvelisib in combination with rituximab in patients with follicular lymphoma. Other global, registration-focused trials evaluating the safety and efficacy of duvelisib are ongoing, including DYNAMOTM, a Phase 2 study in patients with iNHL, and DUOTM, a Phase 3 study in patients with CLL.
Roche also plans to study duvelisib as part of its preclinical and translational efforts in hematology. These research efforts will be part of Roche’s ongoing efforts to further understand the therapeutic potential of Gazyva in combination with both approved medicines and experimental therapies.
“Duvelisib targets both PI3K-delta and PI3K-gamma, two proteins that play critical roles in the growth and survival of tumor cells,” stated Vito Palombella, Ph.D., chief scientific officer at Infinity. “We are pleased that Roche’s preclinical and translational science teams will be studying duvelisib in combination with Gazyva to understand how they may work together. We hope Roche’s research will contribute to our understanding of how duvelisib works in combination with other therapies, including Gazyva, as we seek to improve outcomes for patients.”
About the Development of Duvelisib for the Treatment of Blood Cancers
Infinity is developing duvelisib, an oral inhibitor of Class I PI3K-delta,gamma. The PI3Ks are a family of enzymes involved in multiple cellular functions, including cell proliferation and survival, cell differentiation, cell migration and immunity. The PI3K-delta,gamma isoforms are preferentially expressed in leukocytes (white blood cells), where they have distinct and mostly non-overlapping roles in immune cell development and function. Targeting PI3K-delta and PI3K-gamma may provide multiple opportunities to develop differentiated therapies for the treatment of hematologic malignancies as well as inflammatory diseases.
In 2013, Infinity launched the DUETTSTM (Duvelisib Trials in Hematologic Malignancies) program, a worldwide investigation of duvelisib in blood cancers. As part of the DUETTS program, patient enrollment is ongoing in DYNAMOTM, a Phase 2 monotherapy study designed to evaluate the safety and efficacy of duvelisib in patients with refractory indolent non-Hodgkin lymphoma (iNHL) (ClinicalTrials.gov Identifier NCT01882803), and DUOTM, a Phase 3 monotherapy study designed to evaluate the safety and efficacy of duvelisib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) (NCT02004522). DYNAMO+RTM, a Phase 3 study of duvelisib in combination with rituximab in relapsed follicular lymphoma (NCT02204982), is expected to start in 2014.
Additionally, a Phase 1 study of duvelisib in patients with advanced blood cancers is ongoing (NCT01476657).
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to people with difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. For more information on Infinity, please refer to the company’s website at www.infi.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the Company’s expectations about: the supply of Gazyva by Roche; the therapeutic potential of duvelisib as a monotherapy and in combination with other therapies such as obinutuzumab; plans to initiate additional clinical trials with duvelisib; and its ability to execute on its strategic plans. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company’s current expectations. For example, there can be no guarantee that Infinity will initiate clinical trials in the time frames it has estimated, that any product candidate Infinity is developing will successfully complete necessary preclinical and clinical development phases, or that development of any of Infinity’s product candidates will continue. Further, there can be no guarantee that Roche will meet its obligations under the master clinical supply agreement, or that any positive developments in Infinity’s product portfolio will result in stock price appreciation. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: Infinity’s results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Infinity’s ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of agents by Infinity’s competitors for diseases in which Infinity is currently developing or intends to develop its product candidates; and Infinity’s ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing. These and other risks which may impact management’s expectations are described in greater detail under the caption “Risk Factors” included in Infinity’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 11, 2014, and other filings filed by Infinity with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Stock Continues Trading on the OTCQB
DEERFIELD BEACH, FL–(Sep 3, 2014) – PEN Inc. (OTCQB: PENC) (PEN) today announced that, effective immediately, the company will trade on the OTCQB exchange under the trading symbol PENC.
The new symbol reflects the name of PEN Inc., the new company created by the combination of Applied Nanotech Holdings, Inc. and NanoHoldings, Inc., the parent company of Nanofilm, Ltd.
PEN is one of the country’s leading companies focused on developing and commercializing advanced-performance products enabled by nanotechnology. The company unites staff and resources in nanotechnology research and development and experience in specialty product commercialization.
About PEN Inc. (OTCQB: PENC)
PEN Inc. (PENC) is a global leader in developing, commercializing and marketing enhanced-performance products enabled by nanotechnology. The company focuses on innovative and advanced product solutions in safety, health and sustainability. For more information about PEN Inc, visit www.pen-technology.com.
Safe Harbor Statement
This press release contains forward-looking statements that involve risks and uncertainties concerning our business, products, and financial results. Actual results may differ materially from the results predicted. More information about potential risk factors that could affect our business, products, and financial results are included in our annual report on Form 10-K for the fiscal year ended December 31, 2013, and in reports subsequently filed by us with the Securities and Exchange Commission (“SEC”). All documents are available through the SEC’s Electronic Data Gathering Analysis and Retrieval System (EDGAR) at www.sec.gov or from our website listed above. We hereby disclaim any obligation to publicly update the information provided above, including forward-looking statements, to reflect subsequent events or circumstances.
Contact Information:
Lynn Lilly
Director of Communication
PEN Inc.
Email Contact
(844)2PEN INC x705
IRVINE, Calif., Sept. 3, 2014 — Universal Bioenergy Inc., (OTCPINK:UBRG), a publicly traded diversified energy company that markets and distributes natural gas, petroleum, coal and electricity, announced that its subsidiary NDR Energy Group signed an agreement to supply natural gas to one of the top five largest electric and gas power companies in America. The agreement is projected to generate tens of millions of dollars in additional revenue for the Company from the sales of natural gas.
Universal Bioenergy posted sales of $58.29 million for the nine months ended March 31, 2014, which was a 41.19% increase over the same period last year.
According to the utility customer, it is one of the nation’s largest producers and transporters of energy, and has a portfolio which includes thousands of megawatts of electric power generation, thousands of miles of natural gas transmission pipelines and thousands of miles of electric transmission lines. The utility serves energy customers in 10 states, and operates one of the largest natural gas storage systems in the nation, with hundreds of billions of cubic feet of storage capacity. The utility customer is traded on the New York Stock Exchange and reported over $13.12 billion in revenues in their 2013 Annual Report.
NDR Energy Group’s President and CEO, Ken Harris stated, “At the beginning of 2014, we set out on a difficult course to substantially increase our customer base. In that we already had contracts with some of the largest utilities in the US, we knew that maintaining and growing a customer base of first-in-class, large utilities would have been challenging. This new contract is with one of the five largest electric utilities in the U.S. Additionally, this new customer will be one of the most powerful energy companies concerning the natural gas trades for years to come. There are many potential future synergies concerning this transaction, including our exploration of natural gas exports. In the last six months, we have entered into contracts with two of the five largest electric utilities in the US. These continue to be exciting times for NDR.”
Universal Bioenergy is a high growth diversified energy company that is experiencing double-digit growth. NDR Energy Group, a subsidiary of Universal Bioenergy, sells natural gas to many of the largest public utilities, electric power producers and local gas distribution companies that serve millions of commercial, industrial and residential customer in the United States. The contract limits NDR Energy from disclosing the customer’s name and certain details of the transaction.
About Universal Bioenergy Inc.
Founded in 2004, Universal Bioenergy Inc., is a publicly traded independent diversified energy company that produces and markets natural gas, petroleum, coal and propane. We market energy resources to the largest public utilities, electric power producers and local gas distribution companies in the U.S., that serve millions of commercial, industrial and residential customers. We are also engaged in the acquisition and development of existing or recently discovered oil and gas fields, leases and surface coal mines. For more information visit www.universalbioenergy.com
For inquiries contact: Media Relations: Solomon Ali at 980-225-5376
Safe Harbor Statement – There are matters discussed in this media information that are forward looking statements within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. Such statements are only forecasts and actual events or results may differ materially from those discussed. For a discussion of important factors which could cause actual results to differ from the forward looking statements, refer to Universal Bioenergy Inc.’s most recent annual report and accounts and other SEC filings. The company undertakes no obligation to update publicly, or revise, forward looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required.
PALO ALTO, Calif., Sept. 2, 2014 — Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the launch of a study on human adipose derived mesenchymal progenitor cell (haMPC) therapy for Cartilage Defects (CD) resulting from osteoarthritis (OA) or sports injury. Both arthroscopy and the use of magnetic resonance imaging (MRI) will be deployed to further demonstrate the regenerative efficacy of ReJoinTM on cartilage defects.
“In light of the promising Knee Osteoarthritis Phase IIa six month follow-up results we decided to explore the efficacy of our proprietary ReJoinTM therapy on an additional orthopedic indication, Cartilage Defects (CD),” said Dr. William (Wei) Cao, Chief Executive Officer of the Company. “We are thankful for the approval by the ethics committee of Shanghai Ninth People’s Hospital for this exploratory clinical research, and very much look forward to finding the promise of ReJoinTM therapy on CD. The repair of CD would greatly improve the quality of life for CD patients, allowing for greater mobility, flexibility and less pain.”
About the Study
The clinical study is a single-blind, randomly assigned, controlled clinical research study that will enroll thirty patients with the purpose of evaluating the safety and efficacy of haMPCs combined with lavage, debridement, and/or microfracture under arthroscopy treatment for cartilage defects. In addition, this study shall serve as a supporting study of ReJoinTM for the treatment of Knee Osteoarthritis (KOA) so as to bring additional clinical data to the protocol of future KOA trials.
The study will be conducted by Shanghai Ninth People’s Hospital, a leading teaching hospital affiliated with Shanghai Jiao Tong University School of Medicine. Professor Wang You, Director of the hospital’s orthopedics department and Vice Chairperson of the Chinese Knee Society, will lead the study as Principal Investigator.
About CD in China
Currently in China KOA patients number over 57 million. The incidence of cartilage defect in routine knee arthroscopies has been reported to be almost 300,000 per year. (Source: Market analysis of Chinese arthroscopy, published on July 21, 2014 and “Advances in Orthopedics” Volume 2012, Article ID 528423) Similar to KOA, CD is an unmet orthopedic medical need.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 646 284-9427
vivian.chen@grayling.com
FotoYapp allows users to engage social media on a global scale
NEW YORK, NEW YORK–(Sept. 2, 2014) – Yappn Corp. (OTCQB:YPPN) has begun to roll out its widely anticipated global media and social sharing platform, FotoYapp, in major app stores for iPad ®, iPhones® and Android® devices. Along with its desktop, portable and mobile web browser versions at www.fotoyapp.com in 67 languages, FotoYapp is establishing a truly global experience for users and brands around the world to create social engagement connected to social content in the native language of the user.
FotoYapp allows viewers and users around the world to share images, 18 second video and social comments in their native language, promoting Global Storytelling together with sites like Facebook®, Instagram®, Twitter®, Pinterest®, Flickr®, Tumblr® and Google+® in almost any language.
“FotoYapp allows images that were individually shared across a single network or language to cross-pollinate, sharing among many networks and many languages, creating global social media,” said David Lucatch, founder and CEO of Yappn Corp.
For brands, celebrities and athletes, FotoYapp creates the ability to reach a larger audience in their native language and communicate brand messages globally through images and social content. FotoYapp’s Official solution provides a robust set of features not found anywhere else, allowing for customized control of content, time elements and user engagement opportunities in multiple languages.
On May 13, 2014, Yappn announced its business agreement with Getty Images allowing consumers to have access to some of the world’s best imagery through select Getty Images collections offered on FotoYapp, providing new opportunities to create global social engagement with content.
FotoYapp provides the ability to garner global data results in 67 languages through activities on its online and mobile platforms forming the basis for revenue programs that focus on how content and multi-lingual context interact to enable interactive, sponsorship and monetary associations.
“We’re very excited to announce the launch of FotoYapp in the app stores and online,” added Lucatch. “FotoYapp enables a global voyage of discovery connecting images and video with social context providing an opportunity to story tell and create brand awareness in 67 languages.”
For more information on FotoYapp, please visit www.fotoyapp.com/ and www.yappn.com
About Yappn
Yappn is a real-time multilingual company that amplifies brand messaging, helps conduct commerce and provides customer support by globalizing these experiences with its proprietary approach to language. Through its real-time multilingual amplification platform, Yappn eliminates the language barrier, allowing the free flow of communications in 67 languages. Yappn has developed cost effective, unique and proprietary technology tools and services that create dynamic solutions that enhance a brands messaging, media, e-commerce and support platforms.
In addition to Yappn, FotoYapp (www.fotoyapp.com) provides consumers, brands and Influencers with the ability to share media content (images, video, audio, etc.) instantly across the global social sphere with all major social posts in a single environment in almost any language allowing global participants to interact with each other, regardless of their native tongue.
Yappn Corp. is publicly in the U.S. on the OTCQB – symbol “YPPN” and leading technology incubator; Intertainment Media Inc. (TSX VENTURE:INT)(OTCQX:ITMTF)(FRANKFURT:I4T) has a controlling interest in Yappn Corp.
For more information, please visit http://corporate.yappn.com
Forward Looking Information
Legal Notice and Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, and those preceded by or that include the words “believes,” “expects,” “given,” “targets,” “intends,” “anticipates,” “plans,” “projects,” “forecasts” or similar expressions, are “forward-looking statements.” Although Yappn Corp.’s management believes that such forward-looking statements are reasonable; it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company’s filings with the SEC including the Current Report on Form 8-K filed on April 3, 2013 and each subsequently filed Quarterly Report on Form 10-Q and Current Report on Form 8-K. The Company assumes no obligation to update any of the information contained or referenced in this press release.
Corporate Contact
David Lucatch
Founder and CEO
Yappn Corp.
info@yappn.com
Media Contact
Melissa Kubrin
Fingerprint Communication
melissa@fingerprintcom.net
Dr. Nelson Ludlow, Ph.D., CEO of Intellicheck Mobilisa, Inc. (NYSE MKT:IDN), a global leader in identity solutions and wireless security systems, was interviewed on Fox Business News on September 2 about measures individuals can take to ensure their personal security when dealing with banks.
Speaking with Fox Business News host Maria Bartiromo, Dr. Ludlow noted that recent bank hackings are sophisticated and global in nature, and just as large U.S. banks are taking measures to enhance their cybersecurity, individuals can also take specific steps to enhance their personal security. These steps include noticing any unusual activity on bank statements and reporting it to the bank immediately, and using debit cards—whose PIN numbers provide an extra layer of security—whenever possible.
To view the Fox Business News interview in its entirety, please visit the following link: http://video.foxbusiness.com/v/3763037033001/hacking-411-how-to-beef-up-security/ – sp=show-clips/featured
About Intellicheck Mobilisa
Intellicheck Mobilisa is a leading technology company providing wireless technology and identity systems for various applications, including mobile and handheld access control and security systems for the government, military and commercial markets. Products include the Fugitive Finder system, an advanced ID card access control product currently protecting military bases and secure federal locations; ID Check, a patented technology that instantly reads, analyzes, and verifies encoded data in magnetic stripes and barcodes on government-issued IDs, designed to improve the Customer Experience for the financial, hospitality and retail sectors; barZapp™, an ID-checking mobile app that allows a user’s smartphone to check an ID card. For more information on Intellicheck Mobilisa, please visit www.icmobile.com.
Safe Harbor Statement
Certain statements in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. When used in this press release, words such as “will,” “believe,” “expect,” “anticipate,” “encouraged,” and similar expressions, as they relate to the company or its management, as well as assumptions made by and information currently available to the company’s management identify forward-looking statements. Actual results may differ materially from the information presented here. Additional information concerning forward-looking statements is contained under the heading of risk factors listed from time to time in the company’s filings with the SEC. We do not assume any obligation to update the forward-looking information.
DALLAS, Sept. 2, 2014 — South American Properties, Inc. (Pink Sheets:SAMP), is pleased to announce that the 2013 annual shareholder meeting was held on Dec. 31, 2013. At that time, the 3 proposals previously announced, which included adding 2 new members to the Board, adopting new Bylaws and amending the Articles of Incorporation, were voted on at the meeting and passed. Mr. Scott Horne delivered the new Corporate Vision and laid out the business plan for the company’s new business venture. During this Shareholder meeting, SAMP received approval to change its name to LTV Funding Corp. This information is on the website www.southamericanproperties.com/annual-meeting-info.html.
South American Properties had to cancel its investment opportunity in South America, as was previously announced, due to a shareholder’s action. This was also the reason for the delay in this announcement.
The new direction of the company is as an asset based or “hard money” lending company to residential and commercial real estate investors. The members of the Board have been involved as owners and operators of other asset based lending operations for over 15 years each. Their expertise in this arena should enable the growth and shareholder value to increase in the company beginning this year.
Following the shareholders’ meeting, the board met and Mr. Jeff Love resigned as President and Chairman of the Board. Mr. Horne was elected as the company’s new President and Chairman. In the following weeks, a more detailed plan to raise capital and begin operations and marketing to real estate investors will be introduced. Currently, steps are being taken to file the necessary paperwork to change the name of the corporation to the shareholder approved name.
As LTV Funding Corp. launches into its new operations in 2014, we are seeking to raise capital in both the public and private markets. Opportunities exist for investors of all sizes to invest with LTV Funding, generating both an attractive interest rate as well as a convertible note arrangement. For more information regarding these opportunities, please visit our website, www.ltvfunding.com.
About LTV Funding Corp:
South American Properties, Inc., formerly Texas Hills Barbecue, Inc. now known as LTV Funding, Inc., is a Nevada Corp. based in Dallas, Texas, will lend acquisition and rehab money for commercial and real estate properties, and other income generating assets located in Texas. The Company believes significant opportunities exist in this arena, and it plans to leverage its close relationships with its investor contacts in Texas. LTV may also enter into real estate projects in other states in the near future.
Forward-Looking Statements
This press release may contain forward-looking statements. The words “believe,” “expect,” “should,” “intend,” “estimate,” “projects,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company’s current expectations and are subject to a number of risks, uncertainties and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company’s filings and disclosures at www.OTCmarkets.com.
CONTACT: Scott Horne
scott@ltvfunding.com
LTV Funding Corp, f/k/a South American Properties, Inc.
1400 Gables Court
Plano, Tx 75075
Phone: 214/626-8566
www.ltvfunding.com
Email: scott@ltvfunding.com
Company Enhances Internet Presence With Updated Information and Modernized Design
LA JOLLA, CA–(Sep 2, 2014) – AV1 Group, Inc. (OTC: AVOP), an emerging development company and partner, is pleased to announce the launch of its newly revamped website, AV1Group.com. The new design offers a newly renovated platform with an improved layout, and enhanced navigation through multiple pages reflecting updated details regarding its sectors.
Investors interested in AV1 Group and the ventures of its subsidiaries will find relevant and useful information on the new website under the respective tab of each sector. This new website launch takes into account several considerably informative features, including the recently released specification guide and marketing brochure for its new GrowthSpectrum technology designed to be sold through its CannaLighting division. To download the brochure please go to: AV1Group.com/GrowthSpectrum/
Additional updates and new features can be expected in the future as the Company continues to expand and develop its subsidiaries. Interested parties can view the website at: AV1Group.com
“This is a pivotal step in our preparation to bring serious attention to our Company. We stand on the threshold of great developments, and our newly designed site will more accurately reflect our Company and its preparation for growth in the different segments of the Cannabis industry,” stated Bryen Beglinger, CEO of AV1 Group, Inc.
About AV1 Group, Inc.: AV1 Group, Inc. is a publicly traded investment and holding company established to identify, secure, and monetize emerging growth companies in a number of sectors that include cannabis related technologies, cultivation and ecommerce businesses positioned for exponential growth.
The Company seeks to discover inspired entrepreneurs with revolutionary concepts which can make a substantial footprint in markets that the Company believes to have exponential growth potential. AV1 Group, Inc.’s comprehensive business model also includes a division which delivers internally created projects that are poised for revenue generation, and a platform enabling the Company to develop embryonic stage subsidiaries under one umbrella, bringing a spectrum of backgrounds to the table, thus providing a significant resource of experience, knowledge and expertise to every venture. AV1 Group, Inc. explores every opportunity to help each sector exceed their revenue goals while building close, active working relationships; preparing each respective division to be a robust competitor in their chosen markets. For more information visit: http://www.av1group.com/
Safe Harbor Act: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
EULESS, TX–(Sep 2, 2014) – Dig-it Underground, Inc. (PINKSHEETS: DIGX) – Robert Wodarczyk, President of Dig-it Underground, Inc., announced today that the company has signed a Letter of Intent to acquire 100% of the Membership Interests of Cannabeez Media, LLC along with all its assets and proprietary property, including the web site www.cannabisexaminer.com. Mr. Wodarczyk added, “We are very excited about our entry into the Cannabis Industry and we are optimistic that our relationships will pave the way for significant revenue and earnings increases throughout 2014.” We look forward to updating our shareholders as to our progress with respect to this acquisition.
Safe Harbor Forward – Looking Statements To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward – looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward – looking statement contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Investor Relations Contact:
Robert Wodarczyk
817-797-7600
